HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry.

AbstractBACKGROUND:
The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization.
OBJECTIVE:
We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score.
METHODS:
MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score ≤ 3 and intermediate-to-high (IHBR) for score > 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-driven target lesion revascularization (TLR). Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definition. Dual antiplatelet therapy (DAPT) cessation was independently adjudicated.
RESULTS:
The study included 56% (n = 1270) LBR and 44% (n = 1009) IHBR patients. Incidence of 1-year TLF was higher in IHBR patients (4.1% vs. 2.6%, p = 0.047) driven by cardiac death (1.7% vs. 0.7%, p = 0.029) with similar rates of MI (1.8% vs. 1.1%, p = 0.17), TLR (1.5% vs. 1.6%, p = 0.89) and definite/ probable stent thrombosis (1.2% vs. 0.6%, p = 0.16). Incidence of 1-year major BARC 3 or 5 bleeding was significantly higher in IHBR patients (2.3% vs. 0.9%, p = 0.0094), as was the incidence of DAPT cessation (29.3% vs. 22.8%, p < 0.01), driven by physician-guided discontinuation.
CONCLUSIONS:
Patients with intermediate-to-high PARIS bleeding risk in the MASCOT registry experienced greater incidence of 1-year TLF, major bleeding and DAPT cessation than LBR patients, without significant differences in stent thrombosis.
AuthorsJaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa B Aquino, Petr Hájek, Borislav Atzev, Martin Hudec, Tiong Kiam Ong, Martin Mates, Borislav Borisov, Hazem M Warda, Peter den Heijer, Jaroslaw Wojcik, Andres Iniguez, Zdeněk Coufal, Ahmed Khashaba, Muhammad Munawar, Robert T Gerber, Bryan P Yan, Paula Tejedor, Petr Kala, Houng Bang Liew, Michael Lee, Deborah N Kalkman, George D Dangas, Robbert J de Winter, Antonio Colombo, Roxana Mehran, MASCOT investigators
JournalInternational journal of cardiology. Heart & vasculature (Int J Cardiol Heart Vasc) Vol. 31 Pg. 100605 (Dec 2020) ISSN: 2352-9067 [Print] Ireland
PMID32953969 (Publication Type: Journal Article)
Copyright© 2020 Published by Elsevier B.V.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: